Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue
2001
Combretastatin-A4 disrupts blood vessel development in normal tissue
publication
Author Information
Author(s): Griggs J, Hesketh R, Smith G A, Brindle K M, Metcalfe J C, Thomas G A, Williams E D
Primary Institution: Department of Biochemistry, University of Cambridge
Hypothesis
Does Combretastatin-A4 function as a tumour-specific anti-vascular agent?
Conclusion
Combretastatin-A4 does not target tumors specifically but affects blood vessels regardless of the type of tissue.
Supporting Evidence
- Combretastatin-A4 is currently undergoing clinical trials as an anti-tumour drug.
- The study found that CA-4 caused pathological changes in normal tissue.
- CA-4 induced multiple, discrete intravascular thrombi.
Takeaway
Combretastatin-A4 is a drug that can harm blood vessels in normal tissues, not just in tumors.
Methodology
The study used the hyperplastic thyroid as a model to investigate the effects of Combretastatin-A4.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website